Global managed-care offering to help bring down treatment costs for 366 million diabetics Actavis and Bioton (WSE:BIO) announced today that they have formed a joint venture company for the

Actavis Group has launched Latanoprost eye drops in seven major European markets, immediately after the patents expired in January. In addition to the UK, France, Sweden, Ireland, Denmark,

Gudbjorg Edda Eggertsdottir, President of Actavis Iceland and the Company’s Strategic Projects lead, has been recognised for her remarkable contribution to healthcare and the national economy in